Improving treatment outcome prediction by characterizing the tumor and tumor micro-environment at single-cell level during treatment with immune-checkpoint blockers in the Pointillism project.

This VIB-GCP collaboration guarantees the further translation of established glycomics-based candidate biomarkers for the three diagnostic challenges into the clinic.